Firefly Neuroscience, Inc. (AIFF) Stock Price & Analysis
Firefly Neuroscience, Inc. (AIFF) rose 0.91% to USD 1.11 as of July 25, 2026 at 03:09 UTC, according to Nexqual real-time market data.
AIFF last closed at USD 1.1; the session ranged USD 1.08–1.15 on volume of 71,455 shares. Market capitalization is $17.32M, with a 52-week range of USD 0.62–3.63 (NCM). Source: Nexqual, July 25, 2026 at 03:09 UTC.
Key Statistics (as of July 25, 2026 at 03:09 UTC)
| Price | USD 1.11 |
|---|---|
| Change | ▲ 0.91% (up) |
| Previous Close | USD 1.1 |
| Open | USD 1.1 |
| Day Range | USD 1.08 – 1.15 |
| 52-Week Range | USD 0.62 – 3.63 |
| Volume | 71,455 shares |
| Market Cap | $17.32M |
| Exchange | NCM |
Technical Analysis (AIFF)
Nexqual's technical model rates AIFF "SELL" based on 1 bullish and 5 bearish signals across 125 daily candles, as of July 25, 2026 at 03:09 UTC.
| Overall Signal | SELL |
|---|---|
| RSI (14) | 30.99 (neutral) |
| vs SMA50 | Below (USD 1.44) |
| MACD | -0.09 (negative) |
Analyst Ratings (AIFF)
Wall Street analysts rate AIFF "None", per Nexqual as of July 25, 2026 at 03:09 UTC.
| Consensus Rating | None |
|---|
Earnings (AIFF)
Source: Nexqual, July 25, 2026 at 03:09 UTC.
Financials & Fundamentals (AIFF)
| Total Revenue | $1.58M |
|---|---|
| Revenue Growth (YoY) | +1027.90% |
| Gross Margin | +51.96% |
| Operating Margin | -414.43% |
| Profit Margin | +0.00% |
| ROE | -131.44% |
| Current Ratio | 1.82 |
| Total Cash | $3.13M |
| Total Debt | $0 |
| Free Cash Flow | $-9.62M |
Source: Nexqual, July 25, 2026 at 03:09 UTC.
Financial Health Score (AIFF)
Nexqual rates Firefly Neuroscience, Inc.'s overall financial health "Weak" across five dimensions, as of July 25, 2026 at 03:09 UTC.
| Growth | Mixed — No data |
|---|---|
| Profitability | Critical — Heavily loss-making — early-stage company |
| Balance Sheet | Mixed — $3M cash, no debt |
| Cash Flow | Weak — FCF negative: -$10M, burning cash |
| Efficiency | Critical — ROE -131%, ROA -45.7% |
Ownership (AIFF)
| Insider Ownership | +28.28% |
|---|---|
| Institutional Ownership | +7.86% |
| Shares Outstanding | 15.61M |
| Float | 14.24M |
| Short % of Float | +5.25% |
Source: Nexqual, July 25, 2026 at 03:09 UTC.
Leadership (AIFF)
Firefly Neuroscience, Inc. is led by Greg Lipschitz (age 36), CEO & Director, per Nexqual as of July 25, 2026 at 03:09 UTC.
| CEO & Director | Greg Lipschitz (age 36) |
|---|---|
| President, COO & Director | David DeCaprio (age 52) |
Major Backers & Investors (AIFF)
Notable institutional backers of Firefly Neuroscience, Inc. include Jane Street Group, LLC, Schonfeld Strategic Advisors Llc, UBS Group AG, according to Nexqual as of July 25, 2026 at 03:09 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Jane Street Group, LLC | 1.15% |
| Schonfeld Strategic Advisors Llc | 1.14% |
| UBS Group AG | 0.85% |
| Fidelity | 0.73% |
| Scientech Research LLC | 0.26% |
| Xtx Topco Ltd | 0.18% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| Vanguard Group | 1.77% |
| BlackRock | 1.29% |
| Geode Capital | 1% |
| State Street | 0.3% |
Source: Nexqual, July 25, 2026 at 03:09 UTC.
From Firefly Neuroscience, Inc.'s Latest SEC 10-K Filing (filed 2026-03-31)
Key Strengths & Strategy (as disclosed to the SEC)
- Firefly Neuroscience, Inc., an artificial intelligence company, develops, markets, and distributes medical devices and technologies that allow high-resolution visualization and evaluation of the complex neurophysiological interconnections of the human brain in North America.
- The company offers the Evoke System, a system used to perform electroencephalographic (EEG) and event-related potential (ERP) assessments, which are analyzed by its cloud-based platform and returned as structured reports designed to support clinical decision-making for various diseases, including depression, anxiety, ADHD, PTSD, MCI, dementia, Parkinson's disease, bipolar disorder, schizophrenia, schizoaffective disorder, ASD, and traumatic brain injury.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| JTAI | Jet.AI Inc. | USD 2.04 | ▼ 15.7% |
| TNON | Tenon Medical, Inc. | USD 0.19 | ▼ 3.65% |
| ATPC | Agape ATP Corporation | USD 2.46 | ▼ 2.77% |
| VTAK | Catheter Precision, Inc. | USD 0.26 | ▼ 32.64% |
| BDRX | Biodexa Pharmaceuticals plc | USD 1.65 | ▼ 3.51% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: July 25, 2026 at 03:09 UTC. This page is informational and not investment advice.